NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
Clinical Trials
37 trialsNCT06603155 2025-12-19
Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)
Duke University
Phase NA Withdrawn
NCT06361810 2025-08-19
PSMA Therapy and Immunotherapy in Kidney Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Withdrawn
NCT04688333 2025-06-26
iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma
City of Hope Medical Center
Withdrawn
NCT02671552 2025-05-02
Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery
Thomas Jefferson University
Phase EARLY_PHASE1 Withdrawn
NCT05418387 2024-11-25
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
University of Arizona
Phase NA Withdrawn
NCT04580836 2024-10-26
MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04603365 2023-05-17
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01769885 2022-08-15
Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer
Roswell Park Cancer Institute
Phase NA Withdrawn
NCT05263609 2022-08-02
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
University of Oklahoma
Phase 2 Withdrawn
NCT04961320 2022-06-09
Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell Carcinoma
City of Hope Medical Center
Phase NA Withdrawn
NCT03035630 2022-02-15
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT03189186 2021-04-05
Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
University of California, Irvine
Phase 1 Withdrawn
NCT04262375 2020-11-17
DOMINATION
University Health Network, Toronto
Phase 2 Withdrawn
NCT03927248 2020-05-07
PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
HealthPartners Institute
Phase 1/2 Withdrawn
NCT03943771 2020-01-27
R3DP-A
University Hospital, Bordeaux
Phase NA Withdrawn
NCT03408561 2019-09-17
Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer
University of Southern California
Phase NA Withdrawn
NCT03111901 2019-07-12
UVA-AM-002
University of Virginia
Phase 1/2 Withdrawn
NCT00538772 2019-07-11
An Exploratory Correlative Study of Biomarkers in Patients With Metastatic Renal Cell Carcinoma Who Have Progressed After Sunitinib Therapy
British Columbia Cancer Agency
Withdrawn
NCT02428335 2019-07-05
Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib
AHS Cancer Control Alberta
Withdrawn
NCT03528057 2019-07-05
Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy
Northwestern University
Phase NA Withdrawn
NCT02867332 2019-03-06
PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
Peking University
Phase 1 Withdrawn
NCT03323710 2019-01-09
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
Military Institute od Medicine National Research Institute
Phase 2 Withdrawn
NCT03226236 2018-11-13
RENALVax-2
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Withdrawn
NCT03149159 2018-06-18
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
Medical University of South Carolina
Phase 2 Withdrawn
NCT02962804 2018-03-05
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
University of Kansas Medical Center
Phase 2 Withdrawn
NCT02370342 2017-12-20
Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small Kidney Masses Undergoing Surgery
University of Southern California
Phase NA Withdrawn
NCT00769990 2017-12-13
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT02307474 2016-03-03
A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT00006126 2015-11-13
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
Northwestern University
Phase 1 Withdrawn
NCT00908739 2015-09-30
Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer
Case Comprehensive Cancer Center
Withdrawn
NCT01688414 2014-07-29
Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer
Stanford University
Phase NA Withdrawn
NCT00025519 2013-07-11
Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer
Fox Chase Cancer Center
Phase 2 Withdrawn
NCT01834183 2013-06-19
Tivozanib + Gemcitabine in Metastatic RCC
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT01616186 2013-04-08
Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
University of California, San Francisco
Phase 2 Withdrawn
NCT00601120 2013-02-27
RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase NA Withdrawn
NCT01070186 2012-07-31
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn